Dermatology Expansion

Quote
anonymous said:
Agree with the poster who said you are being forced out. How many years at Amgen and how high is your base pay? Amgen is glorified PCP big pharma company now and would likely prefer young sheep who will follow their marching orders and pay them 40-50k less than you.
Click to expand...

My base is 133,750 at Amgen. Not crazy about the idea of taking a pay cut to work here. Manger would have to be killer.
 
























Offers are going out fast. Interviewed and getting my offer in less than one weeks time. Felt rushed through the process. interview process took me 5 days. Dying to get out of current job but surprised how quick Incyte is to hire.
 






anonymous said:
Offers are going out fast. Interviewed and getting my offer in less than one weeks time. Felt rushed through the process. interview process took me 5 days. Dying to get out of current job but surprised how quick Incyte is to hire.
Click to expand...

must be nice, I’ve been waiting a month now because there is no DM yet. About to take a different offer
 












anonymous said:
Believe this cream will steal business from dupixent? during my interview I was told it is competing in biologic space. Finding that hard to buy. A topical is a topical no?
Click to expand...

they’re trying to say it’s the first “topical biologic” but that’s a tough sell for me. Dupixent is going after patients where a topical is not advisable Or not adequate (IE: systemic therapy candidates) so it will likely be used as an add on for a topical when BSA involvement is high, if an area that is not ideal for a topical is affected (IE: head, hands, feet), or other factors Like age depending on how good of a sales person your Dupixent rep is. This will likely be competing more with Eucrisa & other topicals which will be much cheaper and likely much safer. One of the number one questionS you need to know that no one seems to have the answer to is how the safety profile changes when you reformulate a JAK inhibitor from a systemic treatment to a topical. Will the warnings that are being slapped on products like Xeljanz and the immunosuppressive qualities of the other JAK inhibitors come with the product in topical form? Food for thought...
 






anonymous said:
they’re trying to say it’s the first “topical biologic” but that’s a tough sell for me. Dupixent is going after patients where a topical is not advisable Or not adequate (IE: systemic therapy candidates) so it will likely be used as an add on for a topical when BSA involvement is high, if an area that is not ideal for a topical is affected (IE: head, hands, feet), or other factors Like age depending on how good of a sales person your Dupixent rep is. This will likely be competing more with Eucrisa & other topicals which will be much cheaper and likely much safer. One of the number one questionS you need to know that no one seems to have the answer to is how the safety profile changes when you reformulate a JAK inhibitor from a systemic treatment to a topical. Will the warnings that are being slapped on products like Xeljanz and the immunosuppressive qualities of the other JAK inhibitors come with the product in topical form? Food for thought...
Click to expand...

More food for thought: doctors already compound this cream. Will be a tougher sell than anticipated when you add that factor to the mix. This will not compete in the biologic arena like they think.
 






anonymous said:
More food for thought: doctors already compound this cream. Will be a tougher sell than anticipated when you add that factor to the mix. This will not compete in the biologic arena like they think.
Click to expand...

how do they do that? Crush up xlejanz with lotion? Lol
but seriously, there’s already a generic for it?
 






anonymous said:
More food for thought: doctors already compound this cream. Will be a tougher sell than anticipated when you add that factor to the mix. This will not compete in the biologic arena like they think.
Click to expand...

believe the company has patents on rux for method of use. If shady pharmacies want to compound, something tells me they will be quick to encounter the wrath of Incyte’s legal team.
 






anonymous said:
they’re trying to say it’s the first “topical biologic” but that’s a tough sell for me. Dupixent is going after patients where a topical is not advisable Or not adequate (IE: systemic therapy candidates) so it will likely be used as an add on for a topical when BSA involvement is high, if an area that is not ideal for a topical is affected (IE: head, hands, feet), or other factors Like age depending on how good of a sales person your Dupixent rep is. This will likely be competing more with Eucrisa & other topicals which will be much cheaper and likely much safer. One of the number one questionS you need to know that no one seems to have the answer to is how the safety profile changes when you reformulate a JAK inhibitor from a systemic treatment to a topical. Will the warnings that are being slapped on products like Xeljanz and the immunosuppressive qualities of the other JAK inhibitors come with the product in topical form? Food for thought...
Click to expand...

who’s saying that?!?! It’s a JAK inhibitor which has no biologic basis. It’s a small molecule drug...do your homework.
 






anonymous said:
who’s saying that?!?! It’s a JAK inhibitor which has no biologic basis. It’s a small molecule drug...do your homework.
Click to expand...


Literally... the regional manager I had my phone screen with said those words exactly... and that’s when I knew I did not want this drug or to be a part of this sales team... Check your ego at the door bro, you’re not always the smartest person in the room...
 


















With only a 120 cap on base pay, it won't attract currently employed top performers. More like the desperate laid off workers or PCP reps looking to get 1st oppprtunity in specialty sales.
 






anonymous said:
With only a 120 cap on base pay, it won't attract currently employed top performers. More like the desperate laid off workers or PCP reps looking to get 1st oppprtunity in specialty sales.
Click to expand...

My thoughts exactly. And even the good PCP reps may not leave for 120 unless they are at a bad company and/or just want to get into derm
 






anonymous said:
Literally... the regional manager I had my phone screen with said those words exactly... and that’s when I knew I did not want this drug or to be a part of this sales team... Check your ego at the door bro, you’re not always the smartest person in the room...
Click to expand...

So if you don’t want the job, what’s the point of coming on CP to broadcast that? Popping off on an anonymous chat board screams of insecurity.
 


















Top Bottom
Back
Quote